Prognostic Assessment in Patients with Indolent B-Cell Lymphomas by Luca Arcaini, Sara Rattotti, Manuel Gotti, Stefano Luminari

“…A widely accepted prognostic tool for clinical usage for indolent non-follicular B-cell lymphomas is largely awaited. In this paper we summarized the current evidence regarding prognostic assessment of indolent follicular and non-follicular lymphomas.…”
Get full text

Editorial: T and B cell immune dynamics in allergic response by Mrinmoy Das, Tarun Keswani

Subjects: Get full text

Role of Regulatory B Cells in the Progression of Cervical Cancer by Zhifang Chen, Yuejie Zhu, Rong Du, Nannan Pang, Fengbo Zhang, Di Dong, Jianbing Ding, Yan Ding

Get full text

CAR-T Therapy Beyond B-Cell Hematological Malignancies by Martina Canichella, Paolo de Fabritiis

“…Despite the advances of CAR-T cells in certain hematological malignancies, mostly from B-cell derivations such as non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, a significant portion of other hematological and non-hematological pathologies can benefit from this innovative treatment, as the results of clinical studies are demonstrating. …”
Get full text

MYC Negative Rectal B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt’s Lymphoma in an Immunocompetent Patient by Jignesh G. Parikh, Ted Strom, Ilya Stone

“…B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma (BLUI) is a recently added entity to the World Health Organization (WHO) classification to address a grey zone between large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL). …”
Get full text

Changes in and Potential Mechanisms of Circulating IgA+CD27-Class-Switched Memory B Cells in Patients With Allergic Rhinitis by Zheng H, Xu S, Yang R, Jiao WE, Qiao YL, Liu JY, Fan HM, Zhou YT, Ni HF, Chen J, Deng YQ, Chen SM

Subjects: “…memory b cell…”
Get full text

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas by Pinelopi Argyriou, Panagiota Economopoulou, Sotirios Papageorgiou

“…The purpose of this paper is to summarize the existing knowledge about mTOR inhibitors and their use in the treatment of B-cell lymphomas. Relevant issues regarding mTOR biology in general as well as in B-cell lymphoid neoplasms are also discussed in short.…”
Get full text

Multifocal Extranodal Involvement of Diffuse Large B-Cell Lymphoma by Devrim Cabuk, Y. Taha Gullu, Ilknur Basyigit, Ozgur Acikgoz, Kazım Uygun, Kursat Yildiz, Fusun Yildiz

“…The pathological examination of bronchoscopic biopsy specimen reported diffuse large B-cell lymphoma and the patient was accepted as the endobronchial recurrence of sigmoid colon NHL. …”
Get full text

Studies on the Tissue-Related Phenotypic Heterogeneity of Murine B Cells by Péter Balogh, Attila Kumánovics, Istvan Juhasz

Subjects: “…B cells…”
Get full text

Linking Complement C3 and B Cells in Nasal Polyposis by Ulrike Werner, Axel Künstner, Maren Drenckhan, Ralph Pries, Karl-Ludwig Bruchhage, Hauke S. Busch, Claus Bachert, Barbara Wollenberg

“…Our data suggest a prominent role for the C3-C3aR-axis in nasal polyps and, for the first time, describe a B cell population containing high levels of intracellular C3, suggesting a new role of B cells in the maintenance of the inflammation by complement.…”
Get full text

Pathological Role of Tonsillar B Cells in IgA Nephropathy by Yusuke Suzuki, Hitoshi Suzuki, Junichiro Nakata, Daisuke Sato, Tadahiro Kajiyama, Tomonari Watanabe, Yasuhiko Tomino

“…Emerging evidence indicates that B cells in mucosal infections, particularly in tonsillitis, may produce the nephritogenic IgA. …”
Get full text

Role of Bruton's Tyrosine Kinase in B Cell Development by Alex Maas, Rudolf W. Hendriks

Subjects: “…B cell development…”
Get full text

Gene expression profiling in B-cell non-Hodgkin lymphomas by Renas N. Saleem, Ahmed Khudair Yassin

Subjects: “…b-cell non-hodgkin lymphoma…”
Get full text

Epiphyseal Primary Diffuse Large B-Cell Lymphoma of Bone by Shachar Kenan, Leonard Kahn, Morris Edelman, Arlene Redner, Samuel Kenan

Get full text

Diffuse Large B Cell Lymphoma Mimicking Granulomatosis with Polyangiitis by Mohammad E. Naffaa, Alexander P. Rozin, Netanel Horowitz, Ofer Ben-Itzhak, Yolanda Braun-Moscovici, Alexandra Balbir-Gurman

“…We present an unusual case of a young male with B cell lymphoma who presented with symptoms mimicking systemic vasculitis and review the existing literature.…”
Get full text

Intravascular Large B-Cell Lymphoma Mimicking Temporal Arteritis by Ifeyinwa Emmanuela Obiorah, Metin Ozdemirli

“…The majority of the cases are of B-cell lineage, although rare examples of T or NK lineage have also been reported. …”
Get full text

CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA by Ugo Testa, Simona Sica, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“…Antigens expressed on B-cells, such as CD19, CD20, and CD22, represent targets suitable for treating patients with R/R B-ALL. …”
Get full text

Non-diffuse Large B-cell Lymphoma. Case Presentation by Miguel Ángel Serra Valdés, Yasniel Borrego Moreno, Marleny Viera García

“…Diffuse B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults characterized by its aggressiveness and wide location. …”
Get full text

Diffuse Large B-Cell Lymphoma with Calf Muscle Localization by Laura Bourdeanu, Rashmi Menon, George Somlo

“…Although diffuse large B-cell lymphoma (DLBCL) usually occurs in the lymph nodes, approximately 30–40% of the time it can have an extranodal site of involvement and it can arise in nearly every body site such as intestine, bone, breast, liver, skin, lung, and central nervous system. …”
Get full text

New bispecific antibodies in diffuse large B-cell lymphoma by Adrian G. Minson, Michael J. Dickinson

“… The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Epcoritamab and glofitamab have both been approved in over thirty countries as monotherapy for DLBCL after two prior treatment lines; odronextamab has recent European approval, and mosunetuzumab is active and is being developed as a combination partner. …”
Get full text